EPFL scientists have created a new computer model that can help better design of allosteric drugs, which control proteins "at a distance". Enzymes are large proteins that are involved in virtually ...
Researchers have mapped a previously unseen drug-binding pocket on PKMYT1, a kinase tied to cancer cell division, using X-ray ...
Geneva, Switzerland, September 4, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...
Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced encouraging ...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today ...
Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, ...
Alzecure Pharma AB has selected a TrkA negative allosteric modulator drug candidate, ACD-137, to advance into the preclinical development phase.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results